Business Context and Reporting Period
This Form 8-K is filed by Neuralstem, Inc. (not Palisade Bio, Inc.) for the reporting period of June 16, 2016. The filing discloses a material definitive agreement amendment and the resignation of a director.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to a specific settlement agreement:
- Settlement Liability Reduction: The company entered into an amendment where I. Richard Garr foregoes two lump sum payments totaling $354,000 ($177,000 each).
- Original Payment Dates: The foregone payments were originally scheduled for January 1, 2017, and March 1, 2017.
Material Changes
There are no period-over-period financial comparisons in this filing. The material changes are operational and legal:
- Agreement Amendment: Modification of the General Release and Waiver of Claims Agreement dated March 2, 2016, reducing future cash outflows by $354,000.
- Board Resignation: I. Richard Garr resigned as a member of the Board of Directors effective immediately on June 16, 2016.
Outlook, Risks, and Management Commentary
Management Commentary: The company stated that Mr. Garr's resignation did not result from any disagreement with the Company regarding operations, policies, or practices.
Risks and Contingencies: The filing does not disclose new risks or contingencies beyond the resolution of the prior claims agreement.
Investor Verification Checklist
- Verify the impact of the $354,000 liability reduction on the company's cash flow projections for 2017.
- Confirm the composition of the Board of Directors following Mr. Garr's immediate resignation.
- Review the attached Exhibit 10.01 (Amendment) and Exhibit 99.01 (Resignation Letter) for any undisclosed conditions.
- Note the discrepancy between the request metadata (Palisade Bio) and the filing registrant (Neuralstem, Inc.).